Algorae Reports Stronger AI Drug-Synergy Results And NSW Health Supply Deal
1AI: $0.010 +0.00% · MC: $18M
Algorae Pharmaceuticals says its AI platform identified approximately 2.5 times the proportion of confirmed synergistic drug combinations achieved by its earlier model in a second independent preclinical validation. Its subsidiary AlgoraeRx was appointed one of several suppliers under a NSW Health contract, with first supply expected in the December quarter, but no minimum orders or spending are guaranteed and the company says the award alone is not expected to materially affect current-year revenue. The company also reported cash of approximately $3 million at quarter-end, with a further $3 million facility undrawn.

Comments